...Jingbo Yu; Emily Bland; Tammy Schuler; Thomas Cordaro; Evan Braunstein Introduction: Ruxolitinib is approved for treatment of myelofibrosis. We evaluated ruxolitinib in patients with anemia (hemoglobin <10 g/dL) or thrombocytopenia (platelet count ≤100 × 10 9 /L) at diagnosis. Methods...

... the characteristics, treatment patterns, and clinical outcomes of patients with myelofibrosis (MF) treated with fedratinib following ruxolitinib failure in Israel’s clinical practice. Methods: This retrospective patient chart review included adults with a physician-reported diagnosis of MF, who initiated fedratinib...

...Lucia Masarova; Prithviraj Bose; Naveen Pemmaraju; Lingsha Zhou; Sherry Pierce; Zeev Estrov; Hagop Kantarjian; Srdan Verstovsek Introduction: Median duration of therapy with the first JAK1/2 inhibitor ruxolitinib (RUX) approved for patients with intermediate or high-risk myelofibrosis (MF) is about...

...Aaron T. Gerds; Jingbo Yu; Robyn M. Scherber; Dilan Paranagama; Jonathan K. Kish; Jay Visaria; Mukul Singhal; Srdan Verstovsek; Naveen Pemmaraju Ruxolitinib is an FDA-approved treatment of intermediate- and high-risk myelofibrosis. In the phase 3 COMFORT studies, ruxolitinib reduced spleen volume...

... registered in the database of the Center for the Study of Myelofibrosis in Pavia, Italy, from 1998 to 2020 (June), and diagnosed with atypical myeloproliferative disorder according to our adjudicated criteria. We studied clinical, histological, cytogenetic, and molecular covariates and risks of thrombosis...

... profile from de novo acute myeloid leukemia (AML). In MPN-AP/BP, TP53 and IDH1/2 are more frequent, whereas FLT3 and DNMT3A are rare. Higher incidence of leukemic transformation has been associated with the most aggressive MPN subtype, myelofibrosis (MF); other risk factors for leukemic transformation...

... of ruxolitinib in combination with post-transplant cyclophosphamide (PTCy). Patents and Methods: Twenty patients with primary or secondary myelofibrosis were prospectively enrolled. Reduced intensity conditioning was performed, followed by allogeneic stem cell transplantation from related ( n = 7) or unrelated...

... deployed but its efficacy and safety profile are not well described in this population. We retrospectively reviewed 42 patients treated with decitabine either alone or in combination with ruxolitinib at our institution: 16 with MPN-BP, 14 with MPN accelerated-phase (MPN-AP), and 12 with myelofibrosis...

...Sabrina Mariani; Giovanna Palumbo; Luisa Cardarelli; Michelina Santopietro; Robin Foà; Fiorina Giona Background: Gaucher disease (GD) and primary myelofibrosis (PMF) share similar clinical and laboratory features, such as cytopenia, hepatosplenomegaly, and marrow fibrosis, often resulting...

... option is a second SCT. We retrospectively analyzed outcomes of the second allo-SCT in 25 patients who received at least 2 allografts from related/unrelated donors due to relapse of acute myeloid leukemia, myelodysplastic syndrome or myelofibrosis after the first SCT. A minority of the acute myeloid...

...G. Duhamel Lymphoid myelofibrosis represents an anatomoclinical syndrome of constant symptomatology characterized predominantly by splenomegaly, few lymphadenopathies, pancytopenia with blood lymphocytosis, and a hypoplastic myelogram comprising lymphocytes and histiocytes. Histological study...

...A. Licht; N. Many; E.A. Rachmilewitz A patient with chronic myeloid leukemia of 5 years duration developed myelofibrosis shortly before death. Severe destructive bone lesions were found preterminally in the femur, ribs, pelvis and skull. Hypercalcemia of 14.2 mg%was present as well. Although...

...P. Boivin; J.-F. Bernard; J. Hakim; M. Wroclans In a study of 26 cases of myeloid splenomegaly with myelofibrosis, the authors find a large incidence of immunization anomalies, principally: positive latex reaction in 8 cases; monoclonal proteins in 3 cases; anti-erythrocyte antibodies in 6 cases...

...Joel L. Moake; Harvey Lebos; Richard J. Warren All karyotypes of unstimulated blood leukocytes from a young adult patient with myelofibrosis myeloid metaplasia contained 2 small extra metacentric chromosomes which may have originated in a leukocyte stem cell line by long-arm breakage in chromosome...

...A.G. Papayannis; N.E. Stathakis; T.C. Economopoulos; G. Arapakis; C. Gardikas Platelet function, blood coagulation and fibrinolysis were studied in 13 patients with myelofibrosis. The main abnormalities were impaired ADP-release and abnormal platelet aggregation with collagen. The delay period...

...T. Barbui; R. Battista; E. Dini Spontaneous platelet aggregation has been studied both in normal subjects and in a group of patients affected by chronic myelogenous leukaemia, myelofibrosis, polycythaemia vera and thrombocythaemia. Cold-induced spontaneous aggregation occurs both in normals...

...John D. Lutton; Richard D. Levere Peripheral blood mononuclear cells from patients with polycythemia vera or myelofibrosis with myeloid metaplasia were studied for their erythroid colony growth characteristics in plasma clot cultures. In both diseases, erythroid colonies formed early in culture...

...Brenda M. Page; Jessie L. Watt; I N. Reid; R.J L. Davidson; W. Walker The diverse spectrum of acquired chromosome abnormalities in a female patient with myelofibrosis and myeloid metaplasia is described. A sequence of karyotypic evolution involving a ring chromosome is postulated. The terminal...

...U. Sjögren Aspirates from bone marrow, spleen and liver were analysed in 10 untreated patients with idiopathic myelofibrosis (MF). The proportion of erythroblasts was higher in the spleen and the liver than in the bone marrow. The mitotic indices of the erythropoietic precursor cells were subnormal...

...Gianluigi Castoldi; Antonio Cuneo; Paolo Tomasi; Luisa Ferrari Cytogenetic analysis was performed on megakaryocyte-enriched cell fractions obtained by separation on discontinuous Percoll gradients from blood, bone marrow, and ascitic fluid of 12 patients with myelofibrosis with myeloid metaplasia...